Gerresheimer stock gains 7.43 percent to EUR 33.67

Published on 10/26/2026 at 16:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LBBW set a EUR 29.00 target on October 6, 2026. Gerresheimer stock costs EUR 33.67 on October 26, 2026, up 7.43 percent versus the Xetra close.

Price and analyst signals

Gerresheimer stock gained 7.43 percent on October 26, 2026.
LBBW raised its target from EUR 28.00 to EUR 29.00 on October 6, 2026.
Gerresheimer stock costs EUR 33.67 at Lang & Schwarz on October 26, 2026 at 4:30 p.m. CET, 7.43 percent above the Xetra close of October 23, 2026, and 0.74 percent below the 52-week high.
Gerresheimer is scheduled to report quarterly results on November 25, 2026.

Gerresheimer, DE000A0LD6E6, Illustration mit AI erstellt.

Gerresheimer stock was trading at EUR 33.67 at Lang & Schwarz on October 26, 2026 at 4:30 p.m. CET, up 7.43 percent versus the Xetra close of October 23, 2026 at EUR 31.34. The move puts the stock 0.74 percent below its 52-week high of EUR 33.92.

Analyst target remains below price

LBBW raised its Gerresheimer target from EUR 28.00 to EUR 29.00 on October 6, 2026, while keeping its Hold rating, according to Goldesel. The new target is 13.87 percent below the Lang & Schwarz price, so the analyst update leaves a clear gap between the quoted level and the valuation reference.

Stock position in the yearly range

Gerresheimer's 52-week range runs from EUR 14.83 to EUR 33.92 as of October 26, 2026. The current euro price is therefore 127.04 percent above the low and 0.74 percent below the high. Year to date, the stock is up 14.50 percent, while the October 26 trading volume was 128,974 shares.

Results date and operating figures

Gerresheimer is scheduled to publish quarterly results on November 25, 2026, according to TickerLandia. The date follows the company's planned final first-half report at the end of November 2026.

In preliminary second-quarter 2026 figures published on September 30, 2026, revenue reached EUR 578 million, up EUR 55 million from the first quarter but down from EUR 614 million in the prior-year quarter. Adjusted EBITDA increased to EUR 102 million from EUR 67 million in the first quarter, yet remained below EUR 126 million a year earlier, according to Gerresheimer. The adjusted EBITDA margin reached 17.60 percent in the quarter, compared with 20.50 percent in the prior-year quarter.

What the price level means

The combination of a price near the yearly high and a target below the quote gives investors two distinct signals. The market price reflects the strong recovery from the yearly low, while the LBBW target remains below both the current quote and the latest 52-week high. Gerresheimer's next results date offers the next scheduled point for testing the recovery in adjusted earnings.

Trading position

Gerresheimer belongs to the healthcare sector and the medical instruments and supplies industry. Its business covers pharmaceutical packaging and drug delivery systems, with the second-quarter figures showing a sequential improvement in adjusted EBITDA but a weaker year-over-year comparison. The stock was trading at EUR 33.67 at Lang & Schwarz on October 26, 2026 at 4:30 p.m. CET, up 7.43 percent versus the Xetra close of October 23, 2026 at EUR 31.34. The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.